A new AI-powered test offers more accurate prediction of breast cancer recurrence risk

A caller survey published successful the diary npj Breast Cancer demonstrates that an artificial quality (AI) exemplary offers much close predictions of recurrence hazard successful patients with early-stage bosom crab than the wide utilized 21-gene Recurrence Score. This research, conducted by a squad from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences, specifically targets hormone receptor-positive (HR+) and HER2-negative disease, the astir communal subtype of bosom cancer, which accounts for astir fractional of each bosom crab cases successful the United States.